Navigation Links
Interleukin Genetics Reports Fourth Quarter and Year End 2007 Financial Results
Date:3/27/2008

d test innovative preventive and therapeutic products. Interleukin currently offers an array of Nutraceuticals and OTCeuticals(R), including Ginkoba(R), Ginsana(R) and Venastat(R) which are sold at the nation's largest food, drug and mass retailers, and has commercialized genetic tests for periodontal disease risk assessment, cardiovascular risk assessment, and general nutrition assessment. Interleukin is headquartered in Waltham, MA. For more information about Interleukin and its ongoing programs, please visit http://www.ilgenetics.com.

Certain statements contained herein are "forward-looking" statements including statements regarding the ability to develop diagnostic, personalized nutritional and therapeutic products to prevent or treat diseases of inflammation and other genetic variations, the ability to screen nutritional compounds for their effects on inflammatory responses and other genetic variations, given specific genetic patterns, the ability to make progress in advancing our core technologies, the ability to identify suitable commercial partners and enter into favorable agreements with them, and our expectations regarding future revenues from the Company's nutritional supplement products. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the risk of market acceptance of products, the risk of technology and product obsolescence, delays in product development, the performance of commercial partners, the availability of adequate capital, the actions of competitors and other competitive risks, the ability to integrate acquired businesses, the ability to maintain relationships with customers, and those risks and uncertainties descri
'/>"/>

SOURCE Interleukin Genetics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. T cell immunity enhanced by timing of interleukin-7 therapy
2. Interleukin Genetics, Inc. Management to Present at Healthcare Conferences
3. Interleukin Genetics to Host Third Quarter 2007 Financial Results Conference Call November 7
4. Genetics Researcher at Childrens Hospital Selected as Howard Hughes Medical Institute Investigator
5. Genetics researcher at Childrens Hospital selected as Howard Hughes Medical Institute Investigator
6. Genetics May Determine Antidepressants Effectiveness
7. Genetics Influence Blood Pressure Medications
8. People with anorexia less likely to be blamed when biology, genetics explained
9. Top10 research advances include studies on genetics and stem cell research, stents
10. Heart attack risk from smoking due to genetics
11. Genetics May Boost Mexican-Americans Risk for Alcoholism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, ... length may be showing a genetic propensity for obesity as ... have been linked to increased body fat, but the same ... muscle, the researchers said. At 1 year, kids with ... and 3, however, these genes were linked to excessive weight ...
(Date:10/22/2014)... Maureen Salamon HealthDay ... A crucial part of conventional in vitro fertilization (IVF) -- ... instead take place in a device inside the vagina, new ... contend that the device, called an INVOcell, might sharply cut ... also make the technology more accessible to those who don,t ...
(Date:10/20/2014)... October 20, 2014 The newly updated ... source of thousands of facts, figures and forecasts on ... 68 medical sector forecast categories the Worldwide Medical ... regional and national views on the worldwide medical market ... The report gives you data for 2010-2019, covering each ...
(Date:10/20/2014)... 2014 ASCNYC (ascnyc.org) is a ... New Yorkers living with HIV/AIDS and other chronic ... recovery and self-sufficiency. Each year, ASCNYC spotlights selected ... through their tireless efforts. , Savills Studley ... has been selected as this year’s honoree for ...
(Date:10/20/2014)... October 20, 2014 Zereana Jess-Huff, a 34-year-old ... Maryland 2014 on a platform to think outside the bra. ... uses her position to raise awareness about women’s other lady ... breast cancer. You say the color pink and everybody knows ... for a fact that it has not been won when ...
Breaking Medicine News(10 mins):Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3
... Parker Named Interim Chief Financial Officer , , ... MDTH ), a healthcare provider focused on high ... cardiovascular disease, today announced that Art Parker, Senior Vice ... Financial Officer. Parker replaces Jeff Hinton, whose employment ...
... Endo Pharmaceuticals (Nasdaq: ENDP ) announced today that it will ... 10, 2009 at 4:30 pm Eastern Time. Dave Holveck, President and ... programs. , , The presentation will be webcast live and can ... the investors section. , , About Endo ...
... Scientists make strides in finding ways to slow tumor ... A protein called PHD2 that regulates blood vessel growth ... researchers who analyzed levels of the protein in tumor ... expression of PHD2, researchers at Stanford University School of ...
... CORAL GABLES, FL (June 5, 2009)--Dengue Fever (DF) and ... viral diseases in the World. Around 50-100 million cases ... of suffering this debilitating and sometimes fatal disease. Dengue ... an interdisciplinary team of researchers from the University of ...
... Interleukin Genetics, Inc. (NYSE Amex: ... President of Research and Development, will present findings that ... to weight-loss in overweight individuals at the American Diabetes ... Aziz will present the Company,s research at 8 a.m. ...
... --- Neighborhoods with restaurants, entertainment, cultural facilities and ethnic ... Chicago than neighborhoods where residents are less likely to ... facilities. , Published in the spring 2009 ... Immunology , the two-year study led by Ruchi Gupta, ...
Cached Medicine News:Health News:Endo Pharmaceuticals to Present at Goldman Sachs 30th Annual Healthcare Conference 2Health News:Researchers develop the first climate-based model to predict Dengue fever outbreaks 2Health News:Interleukin Genetics to Present Research Linking Perilipin Genes to Diet Response at the ADA Annual Meeting 2Health News:Interleukin Genetics to Present Research Linking Perilipin Genes to Diet Response at the ADA Annual Meeting 3Health News:Asthma rates and where you live 2
(Date:10/22/2014)... -- AVACEN Medical announced today that its AVACEN 100 ... by the U.S. Food and Drug Administration. This clearance ... Internet for: the temporary relief of joint pain ... sprains . Logo - http://photos.prnewswire.com/prnh/20141021/153513 ... a sophisticated medical device incorporating over 3,000 firmware instructions ...
(Date:10/22/2014)... , Oct. 21, 2014   BioNano Genomics ... latest genomics research centers to purchase an ... the National Cancer Institute (NCI), NIH Intramural Sequencing ... Before Irys, obtaining a comprehensive view of a ... sequencing (NGS) does not deliver the scalability or ...
(Date:10/22/2014)... , Oct. 22, 2014 InVivo Therapeutics Holdings ... is revolutionizing spinal cord injury (SCI) treatment ... shown to outperform in tissue regrowth in the spinal ... Made from an FDA approved polymer, the scaffold ultimately ... harmless to the human body. NVIV has recently attracted ...
Breaking Medicine Technology:AVACEN Medical Announces FDA Clearance of First Medical Device with Internal Game Mode 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 3InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 2InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 3
... ImmusanT, Inc. announced today it has raised ... Healthcare Partners LLC to advance development of the ... monitoring tool for celiac disease. The proceeds will ... to the point of demonstrating proof-of-concept. ImmusanT expects ...
... Dec. 13, 2011 IRIDEX Corporation (Nasdaq: IRIX ... for Health and Clinical Excellence (NICE) has issued a ... is not as cost effective as conventional laser photocoagulation ... treatment for diabetic macular edema (DME), a swelling of ...
Cached Medicine Technology:ImmusanT Raises $20 Million in Series A Financing to Advance Immunotherapeutic and Diagnostic for Celiac Disease 2ImmusanT Raises $20 Million in Series A Financing to Advance Immunotherapeutic and Diagnostic for Celiac Disease 3UK's National Health System Rejects Drug Therapy for Diabetic Macular Edema 2UK's National Health System Rejects Drug Therapy for Diabetic Macular Edema 3
The Vitek 2 is a fully automated bacteriology system that performs bacterial identification and susceptibility testing analysis using a standard inoculum. It detects resistance and helps combat bacte...
IDS Rapid Yeast Plus, a microbial identification system....
IDS Rapid NH, a microbial identification system....
The Cogent Microbial Luminescence System (MLS) is a superior Rapid microbial detection system for UHT product screening combining proven technology of ATP-bioluminescence with unsurpassed hardware in...
Medicine Products: